Drug intelligence / Profile preview

dextran 40

Development stage
Approved
Lead developer
Pharmacosmos
Modality
Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran, a complex, branched polysaccharide with an average molecular weight of 40,000 daltons. Administered intravenously, it functions primarily as a plasma volume expander by increasing intravascular volume through its colloidal osmotic effect. Beyond volume expansion, Dextran 40 also improves microcirculation by reducing blood viscosity and inhibiting the aggregation and adhesiveness of erythrocytes and platelets. It is indicated for the adjunctive treatment of shock due to various causes such as hemorrhage, burns, surgery, or other trauma. Additionally, it is used as a priming fluid in pump oxygenators during extracorporeal circulation and for the prophylaxis of venous thrombosis and pulmonary embolism, particularly following high-risk surgical procedures like hip surgery.

Brand names
LMD in DextroseLMD in Sodium Chloride
Other names
Dextran-Mlow molecular weight dextran
02

Targets

PLG (Plasminogen)BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on dextran 40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextran 40.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call